Forbion et al. back Ario Pharma
Forbion Capital Partners, Seroba Kernel Life Sciences and New Science Ventures (NSV) have injected £1.9m into UK biotech Ario Pharma.
Ario will use the fresh capital to carry out two separate, placebo-controlled phase-II trials for its XEN-D0501 product, which are expected to begin in the first quarter of 2014.
Forbion recently co-led a €20m funding round for Austria-based Hookipa Biotech in November alongside Sofinnova Partners. The firm's portfolio company, Dutch gene therapy firm uniQure, also recently filed a confidential F-1 form with the US Securities and Exchange Commission for a potential IPO.
Company
Headquartered in Cambridge, Ario is a spinout from ion-channel drug discovery company Xention Pharma.
The company is developing drugs for the treatment of respiratory problems. Its XEN-D0501 product is designed to treat chronic idiopathic coughs, as well as symptoms associated with chronic obstructive pulmonary diseases, which include bronchitis and emphysema.
People
John Ford is the CEO of Ario. Forbion co-founder Sander Slootweg and partner Geert-Jan Mulder both sit on Ario's board of directors alongside Seroba partner Graham Fagg and NSV managing partner Somu Subramaniam.
More on UK / Ireland
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater